A court has denied the motion to dismiss the amended complaint in the securities class action against Acadia Healthcare Company (NASDAQ: ACHC), allowing the litigation to proceed past the early procedural stage. The ruling preserves the claims for investors who purchased or acquired Acadia Healthcare securities during the applicable class period and suffered losses. While the decision does not establish liability or determine the truth of the allegations, it signals that the case will move forward into discovery and further legal proceedings. For shareholders, this means potential exposure to settlement costs and continued scrutiny of the company’s business practices.

The denial of the motion to dismiss means the defendants’ request to end the lawsuit at an early stage was rejected by the Court. According to Robbins LLP, which is reminding investors of their rights, the ruling allows the claims to continue but does not constitute a finding that Acadia Healthcare violated securities laws. The firm notes that investors who fall within the class definition and experienced losses may still have rights in the litigation. If the case settles, Acadia Healthcare will incur expenses including payouts to shareholders and attorney fees, which are paid by defendants if there is a recovery in favor of shareholders.

Allegations in the Class Action

The amended complaint alleges that Acadia Healthcare made false and misleading statements and failed to disclose material information concerning its business practices. Specifically, the lawsuit centers on allegations that the company’s business model involved holding vulnerable patients against their will in facilities, even when such detention was not medically necessary. Additional allegations include:

• Patients at Acadia Healthcare facilities were subjected to abuse.
• Acadia Healthcare allegedly deceived insurance providers into paying for patient stays that were not medically necessary.
• Public statements regarding the company’s business and operations were materially false or misleading due to the failure to disclose these practices and related risks.

Timeline of Disclosures and Market Impact

According to the complaint, information regarding these alleged practices emerged through investigative reporting and subsequent government inquiries. On September 1, 2024, The New York Times published an investigative article titled "How a Leading Chain of Psychiatric Hospitals Traps Patients," detailing individual patient experiences and allegations concerning admission and detention practices. Following this publication, Acadia Healthcare’s stock price fell $3.72 per share, or approximately 4.5%, to close at $78.21 per share on September 3, 2024.

Further developments occurred on September 27, 2024, when Acadia Healthcare disclosed receiving a voluntary request for information from the United States Attorney’s Office for the Southern District of New York and a grand jury subpoena from the United States District Court for the Western District of Missouri. These inquiries concerned the company’s admissions, length-of-stay, and billing practices. Following this disclosure, the stock price fell $12.38 per share, or approximately 6.36%, to close at $63.28 per share on September 27, 2024.

What the Numbers Show

The market reaction to the disclosures highlights the significant financial risk associated with the allegations. The stock decline accelerated from a 4.5% drop following the initial media report to a 6.36% drop after the disclosure of federal government inquiries. This suggests that investors viewed the regulatory scrutiny as a more material threat than the reputational damage from the investigative article alone. The cumulative drop of over 10% in less than a month underscores the sensitivity of Acadia Healthcare’s valuation to operational and compliance risks.

Investors seeking information about their rights in the Acadia Healthcare securities class action may contact Robbins LLP. The firm represents investors on a contingency fee basis, meaning investors do not pay attorney fees or litigation expenses directly.

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) has seen its price target raised by multiple analysts, reflecting an increased valuation outlook for the behavioral healthcare provider. Guggenheim analyst Jason Cassorla maintained a Buy rating on Acadia Healthcare Co and raised the price target from $31 to $38. This follows similar actions by TD Cowen and UBS, who also revised their targets upward, signaling confidence in the company's future performance and operational strength.

Analyst Outlook

TD Cowen analyst Ryan Langston maintains Acadia Healthcare Co with a Buy rating and raised the price target from $30 to $36. Separately, UBS analyst A.J. Rice has maintained a Buy rating on Acadia Healthcare Co and raised the price target to $39 from $31. The revised targets reflect an increased valuation outlook for the healthcare services provider.

The rating upgrades come as firms evaluate Acadia's current market position and growth trajectory. By raising the price targets, TD Cowen, UBS, and Guggenheim indicate potential upside from the previous valuation levels.

Company Overview

As of March 31, 2026, Acadia operated a network of 275 behavioral healthcare facilities with approximately 12,400 beds across 40 states and Puerto Rico. The company employs approximately 25,000 people and serves more than 84,000 patients daily, positioning it as the largest stand-alone behavioral healthcare company in the U.S.